Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 131-137

  Seedhouse, Claire H ^a   Mills, Ken I ^b   Ahluwalia, Sophie ^a   Grundy, Martin ^a,c   Shang, Shili ^a   Burnett, Alan K ^d   Russell, Nigel H ^a,c   Pallis, Monica ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

ABCB1; AML; FLT3 ITD; FOXO1; P glycoprotein

Indexed keywords

CD135 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR RUNX3;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE REPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84890470874     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.030     Document Type: Article

References (40)

1. Burnett A.K., Milligan D., Goldstone A., Prentice A., McMullin M.F., Dennis M., et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology 2009, 145:318-332.
2. Pallis M., Hills R., White P., Grundy M., Russell N., Burnett A. Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. Blood Cancer Journal 2011, 1. 10.1038/bcj.2011.23.
3. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 2006, 5:219-234.
4. Pallis M., Turzanski J., Higashi Y., Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leukemia & Lymphoma 2002, 43:1221-1228.
5. Mahadevan D., List A.F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004, 104:1940-1951.
6. Scotto K.W. Transcriptional regulation of ABC drug transporters. Oncogene 2003, 22:7496-7511.
7. Han C.Y., Cho K.B., Choi H.S., Han H.K., Kang K.W. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 2008, 29:1837-1844.
8. Seedhouse C.H., Grundy M., White P., Li Y., Fisher J., Yakunina D., et al. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2007, 13:7059-7066.
9. Guinn B.A., Gilkes A.F., Woodward E., Westwood N.B., Mufti G.J., Linch D., et al. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysics Research Communications 2005, 333:703-713.
10. Huang H., Tindall D.J. Dynamic FoxO transcription factors. Journal of Cell Science 2007, 120:2479-2487.
11. Tothova Z., Gilliland D.G. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007, 1:140-152.
12. Kiyoi H., Naoe T., Nakano Y., Yokota S., Minami S., Miyawaki S., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
13. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
14. Marzac C., Teyssandier I., Calendini O., Perrot J.Y., Faussat A.M., Tang R., et al. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2006, 12:7018-7024.
15. Pallis M., Das-Gupta E. Flow cytometric measurement of functional and phenotypic p-glycoprotein. Chemosensitivity 2005, Humana Press, Totowa.
16. Pallisgaard N., Clausen N., Schroder H., Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999, 26:355-365.
17. Qian Z., Fernald A.A., Godley L.A., Larson R.A., Le Beau M.M. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proceedings of the National Academy of Sciences of the USA 2002, 99:14925-14930.
18. Liew K.J., Chow V.T. Microarray and real-time RT-PCR analyses of a novel set of differentially expressed human genes in ECV304 endothelial-like cells infected with dengue virus type 2. Journal of Virological Methods 2006, 131:47-57.
19. Seedhouse C.H., Hunter H.M., Lloyd-Lewis B., Massip A.M., Pallis M., Carter G.I., et al. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2006, 20:2130-2136.
20. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434-2439.
21. Rockova V., Abbas S., Wouters B.J., Erpelinck C.A., Beverloo H.B., Delwel R., et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011, 118:1069-1076.
22. Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W., et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004, 116:551-563.
23. Yang Y., Hou H., Haller E.M., Nicosia S.V., Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO Journal 2005, 24:1021-1032.
24. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976, 455:152-162.
25. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Research 2005, 65:9643-9650.
26. Scheijen B., Ngo H.T., Kang H., Griffin J.D. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004, 23:3338-3349.
27. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
28. Pallis M., Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000, 95:2897-2904.
29. Langer C., Radmacher M.D., Ruppert A.S., Whitman S.P., Paschka P., Mrozek K., et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008, 111:5371-5379.
30. Seedhouse C.H., Pallis M., Grundy M., Shang S., Russell N.H. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations. British Journal of Haematology 2009, 147:653-661.
31. Yoshimoto G., Miyamoto T., Jabbarzadeh-Tabrizi S., Iino T., Rocnik J.L., Kikushige Y., et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009, 114:5034-5043.
32. Rombouts E.J., Pavic B., Lowenberg B., Ploemacher R.E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004, 104:550-557.
33. Seedhouse C., Grundy M., Shang S., Ronan J., Pimblett H., Russell N., et al. Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2009, 15:7291-7298.
34. Hunter H.M., Pallis M., Seedhouse C.H., Grundy M., Gray C., Russell N.H. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. British Journal of Haematology 2004, 127:26-33.
35. Owusu-Ansah E., Banerjee U. Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation. Nature 2009, 461:537-541.
36. Novershtern N., Subramanian A., Lawton L.N., Mak R.H., Haining W.N., McConkey M.E., et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 2011, 144:296-309.
37. Jawad M., Seedhouse C., Mony U., Grundy M., Russell N.H., Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2010, 24:74-80.
38. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
39. Frescas D., Valenti L., Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. Journal of Biological Chemistry 2005, 280:20589-20595.
40. Oh W.K., Cho K.B., Hien T.T., Kim T.H., Kim H.S., Dao T.T., et al. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Molecular Pharmacology 2010, 78:855-864.